RxLogix was selected by a European pharmaceutical company to replace their current safety database ARISg with RxLogix End to End Safety platform

21 Feb 2022

Our new partner company develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients for neurological disorders, oncology and respiratory diseases.

The company’s products are marketed in over a hundred countries, and the Group’s own human pharmaceuticals sales organization covers all key European markets and a few Southeast Asian countries. In other markets the company’s products are sold by several collaboration partners. All the company’s manufacturing plants and most of its R&D operations are in Europe.

The following PV business processes will be enhanced as a result of implementing RxLogix Safety platform:

• Case Management
• Reporting
• Signaling
• Quality
• Compliance